Building a next-generation, two-component protein subunit vaccine against monkeypox virus

In this proof-of-concept study, we present a next-generation poxvirus vaccine that features a 'two-in-one' immunogen. Our protein vaccine construct, DAM, combines the monkeypox virus antigens A35 and M1, and was produced on the basis of structure-guided design. The DAM subunit vaccine elicited superior antiviral immunity with safety compared to cocktail vaccines or a live vaccinia virus vaccine.